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Mismatched unrelated donor (MMUD) or umbilical cord blood (UCB) can be chosen as alternative donors for
allogeneic stem cell transplantation but might be associated with long-lasting immune deﬁciency. Sixty-six
patients who underwent a ﬁrst transplantation from either UCB (n ¼ 30) or 9/10 MMUD (n ¼ 36) and
who survived beyond 3 months were evaluated. Immune reconstitution was prospectively assessed at
sequential time points after transplantation. NK, B, CD4þ, and CD8þ T cells and their naïve and memory
subsets, as well as regulatory T cells (Treg), were studied. Detailed analyses on infections occurring after 3
months were also assessed. The 18-month cumulative incidences of infection-related death were 8% and 3%,
and of infections were 72% and 57% after MMUD and UCB transplantation, respectively. Rates of infection per
12 patient-month were roughly 2 overall (1 for bacterial, .9 for viral, and .3 for fungal infections). Memory,
naïve CD4þ and CD8þT cells, naïve B cells, and Treg cells reconstitution between the 2 sources were roughly
similar. Absolute CD4þT cells hardly reached 500 per mL by 1 year after transplantation and most B cells were
of naïve phenotype. Correlations between immune reconstitution and infection were then performed by
multivariate analyses. Low CD4þ and high CD8þT cells absolute counts at 3 months were linked to increased
risks of overall and viral (but not bacterial) infections. When assessing for the naïve/memory phenotypes at 3
months among the CD4þ T cell compartment, higher percentages of memory subsets were protective against
late infections. Central memory CD4þT cells protected against overall and bacterial infections; late effector
memory CD4þT cells protected against overall, bacterial, and viral infections. To the contrary, high percentage
of effector- and late effector-memory subsets at 3 months among the CD8þ T cell compartment predicted
higher risks for viral infections. Patients who underwent transplantation from alternative donors represent a
population with very high risk of infection. Detailed phenotypic analysis of immune reconstitution may help
to evaluate infection risk and to adjust infection prophylaxis.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Only 30% of patients who require an allogeneic hemato-
poietic stem cell transplantation (HSCT) will have an HLA-
matched sibling donor. A search for an unrelated donor will
be undertaken for patients without a matched family donor.
However, for many patients, particularly patients of diverse
racial andethnicbackgrounds, itmaynotbepossible to rapidly
identify a suitablymatched unrelated donor. Three alternative
graft sources, umbilical cord blood (UCB), haploidenticaldgments on page 516.
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14.01.001related donor, and mismatched unrelated donor (MMUD)
are available. UCB is associated with delayed hematologic
recovery and immune reconstitution. Haploidentical trans-
plantation is characterized by donor availability for trans-
plantation but may be complicated by a high risk of graft
failure and relapse. A MMUD transplantation may also be an
option, but graft-versus-host disease (GVHD) and immune
deﬁciency may be of greater concern. Phase 2 studies have
documented advances in HLA typing, GVHD prophylaxis, and
infectionprevention,whichhave improved survival (reviewed
by Ballen et al. [1]). The same patient evaluated in different
transplantation centers may be offered MMUD, UCB, or Hap-
loidentical HSCT depending on center preference. At the
Hospital Saint Louis, Paris, France, our policy has been to
restrict our indication to either MMUD or UCB, depending on
the emergency to transplantation and on technical aspects.
However, after bothUCBandMMUDtransplantations, delayedTransplantation.
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concern [1-4].
Despite advances in antimicrobial therapy, infections
remain a major cause of death after alternative donor HSCT,
particularly in older patients. UCB contains fewer T cells than
other stem cell sources, and UCB lymphocytes have speciﬁc
immunologic characteristics, such as a different response
pattern to cytokines and a greater proportion of naive T cells
[5,6]. In a prospective analysis of immune reconstitution in
UCB recipients and HLA-matched unrelated donor (MUD)
recipients from the Dana Farber Cancer Institute, Jacobson
et al. found that CD3þ T cells recovery was signiﬁcantly
delayed in the UCB group compared with the MUD group for
as long as 6 months after HSCT, including naive and memory
CD4þ T cells, regulatory T cells (Treg), and CD8þ T cells [7].
These unique properties of UCB may contribute to the high
risk of infection reported in some studies. However, this study
compared UCB toMUD and not to MMUD, the most clinically
relevant comparator. So far, no study has compared a cohort
of patients who underwent transplantation either from UCB
or from MMUD with regard to infectious complications and
long-term immune recovery that prompted the report herein.
PATIENTS AND METHODS
Patients
Patients who underwent ﬁrst allogeneic HSCT from either UCB orMMUD
at Saint-Louis Hospital (Paris, France) between January 2005 and December
2010 were considered for this study. Patients with hematological malig-
nancies and aplastic anemia were included. Patients were eligible for HSCT
from 1 of these 2 alternative stem cell sources if they had no available HLA-
matched related or unrelated donor (10/10 HLA-matched with the recipient,
at the allelic level for HLA-A, -B, -C, -DRB1, and -DQB1 loci). According to
institutional guidelines, the algorithm for alternative donor selection was
MMUD ﬁrst, followed by UCB for adult patients and UCB ﬁrst, followed by
MMUD for pediatric patients. HSCT from MMUD was performed either with
peripheral blood stem cells or with bone marrow as graft source. For MMUD
selection, donor/recipient HLA-match was based on the results of high-
resolution molecular typing for HLA-A, -B, -C, -DRB1, and -DQB1 loci and
only 1 mismatch was permitted (9/10 HLA-matched donor). For UCB HSCT,
double-UCB HSCT was performed in patients for whom no single unit of
adequate cell dose (total nucleated cell <1  107/kg) was available. For UCB
unit selection, donor/recipient HLA-matchwas determined by low-resolution
generic oligotyping for HLA-A and -B loci and high-resolution molecular
typing for HLA-DRB1. According to institutional guidelines, UCB units were
3/6 to 6/6 HLA-matched with the recipients and with each other, for double
UCB HSCT. No graft was ex vivo T cell depleted. To study immune reconsti-
tution and infectious outcomes after alternative HSCT, patients who experi-
enced primary or secondary graft failure were excluded from this analysis.
A total of 105 consecutive patients who underwent transplantation from
MMUD (n ¼ 56) or from UCB (n ¼ 49) met inclusion criteria. To assess late
infectious outcomes (>3 months after HSCT) and immune reconstitution
from 3 months after HSCT, 11 patients who died or relapsed in the early
period after HSCT (0 to 3months afterHSCT)were secondarily excluded from
the analysis (MMUD recipients, n ¼ 6; UCB recipients, n ¼ 5). An additional
28 patients were not evaluable because of lack of immune recovery data
(MMUD recipients, n ¼ 14; UCB recipients, n ¼ 14). As a result, 66 patients
were considered for late infectious outcomes and immune reconstitution
analyses. Baseline characteristics of assessable and excluded patients are
compared in Supplementary Table 1. The 2 cohorts were comparable for pre-
HSCTcharacteristicswith the exceptionof recipient gender and recipient age.
Data concerning pretransplantation characteristics and most trans-
plantation outcomes were prospectively collected in our transplantation
database and extracted for this study. Precise data about late infectious
events and the cumulative dose of corticosteroids administered were
retrospectively collected by a review of all medical records. Immune cell
subsets reconstitution was assessed prospectively. All patients provided
written informed consent for use of protected health data for research and
for blood sample collection, in accordance with the Declaration of Helsinki.
The study was approved by the institutional review board.
Transplantation Modalities and Outcomes: Deﬁnitions
Myeloablative conditioning regimens and reduced-intensity condition-
ing were deﬁned as previously described [8]. All patients were treated in
laminar airﬂow rooms and received oral amoxicillin, oﬂoxacine, ﬂuconazole,and acyclovir as prophylaxis. According to local policy, ﬂuconazole was
stopped when patients had an absolute neutrophil count above 1  109/L
and were off corticosteroids. Amoxicillin was continued for at least 5 years
after HSCT. Prophylaxis against Pneumocystis Carinii and Toxoplasmosis was
started after neutrophils recovery and was withdrawn when immunosup-
pressive treatment was discontinued and CD4 count was .4 109/L. Patients
were vaccinated according to European recommendations. While in hospi-
tal, patients were tested twice each week by real time PCR for cytomega-
lovirus and once a week for herpes virus (HSV1, HSV2, HHV6, and EBV),
adenovirus, aspergillus, and toxoplasma until discharge. After patients were
discharged from hospital, the same infection screening was performed once
eachweek until dayþ 100 and at least once eachmonth until 6 months after
hematopoietic stem cell transplantation.
Chronic GVHD was diagnosed according to the 2005 National Institutes
of Health Consensus Criteria [9].
Infectious Events: Deﬁnitions and Monitoring
This study focused on late infectious events, deﬁned as those occurring
beyond 3months after transplantation. Infections were diagnosed according
to standard criteria [10]. Only serious infections potentially associated with
clinical compromise were considered in this analysis, as previously de-
scribed [11]. These include bacterial infections of any organ site requiring i.v.
therapy and/or hospitalization. Other infections not requiring therapy or
those requiring only oral antibiotics on an outpatient basis were excluded
from this study. Bacterial infections were either proven or presumed based
on the combination of clinical presentation and response to treatment with
antibiotics. For example, all microbiologically undocumented pneumonias
that resolved after empirical antibiotics were considered as of bacterial
origin. Bacteremia by coagulase-negative staphylococci, Micrococcus spp,
and saprophytic Corynebacterium spp were not included in this analysis.
Uncomplicated fevers of unknown origin were also excluded because of
potential for reporting bias. Also included are viral infections including
cytomegalovirus infection and disease, Epstein-Barr virus reactivation
requiring treatment, and other documented severe invasive viral infections
requiring i.v. therapy and/or hospitalization (such as disseminated form or
visceral involvement of herpes family virus infections, adenovirus disease,
viral B or C hepatitis, and lower respiratory tract infection by respiratory
viruses). We did not include benign presumably viral upper airway in-
fections and bronchitis, or BK-virus cystitis. CMV infection was deﬁned as
the presence of 1 or more positive quantitative PCR result (more than 1000
CMV DNA copies/mL) that prompted clinicians to initiate pre-emptive
treatment. CMV disease was deﬁned as the demonstration of CMV by his-
tology in biopsy or autopsy specimens from clinically involved visceral sites
or if CMV was detected in samples from clinically deﬁned sites of disease.
Invasive fungal infections involving lung, sinus, central nervous system or all
other organs were also included. Invasive aspergillosis was deﬁned as
proven, probable or possible according to previously reported criteria
(reviewed in [4]). Finally, arasitical infections includes toxoplasmosis and
other invasive parasitical infections were included. Infections were consid-
ered as life threatening if they necessitated intensive care with vasopressors
or mechanical ventilation. Infection-related mortality was deﬁned as death
from infection as primary cause of death, basing on the Copelan hierachical
scheme for causes of death assignment [12].
Immunological Analyses of Lymphocytes Subsets
Immune cell subsets reconstitution was prospectively assessed (as
described in Corre et al. [13]) by ﬂow cytometry on fresh peripheral blood
samples collected at approximately 1 month before HSCT and then at 3, 6,
and 12 months after HSCT. Blood cells were characterized using 4-color ﬂow
cytometry after treatment with a red blood cell lyzing solution. Measure-
ments of forward and side scatter were combined with CD45 and CD14 to
identify lymphocytes and to exclude monocytes. A minimum of 10,000
lymphocytes were analyzed to ensure adequate subset analysis. Antibodies
used were CD45-FITC, CD14-PE, CD3-FITC and CD3-PerCP, CD4-APC-Cy7,
CD8-PerCP, CD45RA-APC and CD45RA-PE-Cy7, CCR7-PE, CD25-PE and
CD25-APC, CD127-PE, CD56-PE, CD19-PE-Cy7 and CD27-PE (all from BD
Biosciences, Le Pont-De-Claix Cedex, France). Appropriate isotype-matched
controls were carried out simultaneously on each sample. The analyzed cell
subsets were T cells (CD3þ), CD4þ T cells (CD3þCD4þ), CD8þ T cells
(CD3þCD8þ), NK cells (CD3CD56þ) and B cells (CD19þ). More detailed T and
B cell phenotypes analyses were also performed if the number of collected
cells was sufﬁcient. The different populations were deﬁned as follows: naïve
CD4þ T cells (CD4þCD45RAþCCR7þ); central memory CD4þ T cells (CD4+
CD45RA-CCR7+); effector memory CD4þ T cells (CD4þCD45RACCR7); late
effector memory CD4þ T cells (CD4þCD45RAþCCR7); Treg (CD4þCD25þ
CD127low); naïve CD8þ T cells (CD8þCD45RAþCCR7þ); central memory
CD8þ T cells (CD8þCD45RACCR7þ); effector memory CD8þ T cells (CD8þ
CD45RACCR7); late effector memory CD8þ T cells (CD8þCD45RAþCCR7);
Table 1
Patient, Disease, and Transplantation Characteristics
Variable mmUD UCB P Value
No. of patients 36 30
Recipient gender .051
Female 15 (42) 20 (67)
Male 21 (58) 10 (33)
Recipient age at
transplantation,
median (range), yr
43 (16-63) 24 (9-56) .0001
<18 3 (8) 8 (27)
18-40 14 (39) 17 (57)
>40 19 (53) 5 (17)
Disease .12
Malignant hematologic
diseases
Acute leukemia 21 (58) 16 (53)
Myelodysplastic
syndrome
5 (14) 5 (17)
Lymphoma 5 (14) 4 (13)
Multiple myeloma 4 (11) 0 (0)
Nonmalignant
hematologic diseases
Aplastic anemia,
acquired
0 (0) 4 (13)
Fanconi 1 (3) 1 (3)
Conditioning .23
Myeloablative 16 (44) 18 (60)
Reduced intensity 20 (56) 12 (40)
Total body irradiation dose .77
No 17 (47) 12 (40)
12 Gy 8 (22) 6 (20)
2 Gy 11 (31) 12 (40)
Antithymocyte globulin
(before transplantation)
13 (36) 11 (37) >.99
Stem cell source d
Peripheral blood 27 (75) 0 (0)
Bone marrow 9 (25) 0 (0)
Cord blood, single 0 (0) 5 (17)
Cord blood, double 0 (0) 25 (83)
Infused cells, median
(range)
Total nucleated cells 
108/kg
9.5 (1.1-22.5) .32 (.12-.82) d
CD34þ  106/kg 6.2 (1.9-34.4) .24 (.12-10.05) d
GVHD prophylaxis <.0001
Cyclosporine/
methotrexate
16 (44) 1 (3)
Cyclosporine/
mycophenolate
mofetil
20 (56) 14 (47)
Other 0 (0) 15 (50)
Donor/recipient CMV
serostatus
.0007
Dþ/R 9 (25) 0 (0)
Dþ/Rþ 5 (14) 0 (0)
D/Rþ 13 (36) 15 (50)
D/R 9 (25) 15 (50)
Neutrophil recovery
within 3 mo.
32 (89) 29 (97) .37
Acute GVHD grade 2e4
within 3 mo.
28 (78) 16 (53) .065
Steroid 3 mo. AUC, median
(range), mg/kg
92.4 (0-234.1) 107.9 (0-261.5) .51
GVHD indicates graft-versus-host disease; D, donor; R, recipient; AUC, area
under the curve.
Data presented are n (%) unless otherwise indicated.
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cytometry was performed on a FACS Canto II (BD Bioscience) and analyzed
using FACS Diva software.
Statistical Analyses
Baseline characteristics of patients who underwent transplantation
from MMUD or UCB, as well as characteristics at 3 months (neutrophil re-
covery acute GVHD and cumulative corticosteroid exposure), were
compared using Wilcoxon rank-sum tests and Fisher’s exact tests. Data are
presented as median (range) or count (percent). Cumulative corticosteroid
dose beginning on the day of transplantation until the 3-month time point
after HSCT was determined by the area under the curve [14]. The main
clinical outcomes were infections: overall infections and then bacterial,
viral, and fungal infections; life-threatening infections; and infection-
related mortality. Other clinical outcomes were chronic GVHD, disease
relapse, nonrelapse mortality (NRM), and overall survival (OS). Because
immune recovery was evaluated in patients alive and relapse free at 3
months, the analysis of time-to-event outcomes was carried out using the
landmarkmethod at 3months; ie, only events occurring after 3months after
transplantation were considered, with follow-up origin at 3 months after
transplantation. Infections and infection-related mortality were censored at
18 month after transplantation because of the lack of reliability of infor-
mation gathered after that time. NRM was considered as time to any death
occurring before disease relapse. NRM and relapse were considered to be
mutually competing risks. Death and relapse were considered as competing
risks for infection. Death was considered as a competing risk for chronic
GVHD. OS was estimated using Kaplan-Meier product-limit estimator. For
competing risks analyses, cumulative incidence functions were estimated
using usual methodology [15]. Moreover, to account for repeated infections,
incidence rates taking into account all infections occurring within 18
months after transplantation were estimated. Comparisons of cumulative
incidence of at least 1 infection were performed by Gray’s test [16]. The
Wilcoxon rank-sum test was used to compare immune cell populations
between MMUD and UCB before transplantation and at 3, 6, and 12 months
after transplantation, with P values adjusted for the repeated comparisons at
the 4 time points using Benjamini-Hochberg’s method to control the false
discovery rate [17]. When comparing cell populations at each time point,
only available data were analyzed.
Univariate and multivariate analyses of early clinical and immunological
factors and late infections risks were performed using Prentice-Williams-
Peterson conditional approach for ordered multiple events [18]. Tested
variables were baseline clinical factors, 3-month clinical factors and 3-
month immunological factors (see Supplementary Table 2). For multivar-
iate analysis, all variable achieving a P value <.10 in univariate analysis were
considered. For multivariate analysis, main immune cell populations were
used as quantitative variables, and subpopulations as percentage of each
main population, to avoid collinearity and disentangle the respective effect
of the main population and its subpopulations. Additional analysis of the
association between circulating immune cells and infection was based on
joint models [19], where a proportional hazards model was used for the risk
of ﬁrst infection of any type, and a linear mixed effects model was used to
model the subject-speciﬁc evolution of immune cell subpopulations. This
allowed analyzing both the dynamics of immune recovery before any
infection, because infection may affect the immune cell subpopulations, and
the association between immune cell counts at any time and the risk of ﬁrst
infection. Thus, use of such model also allows valid estimation under several
patterns of missing data without multiple imputation [20,21]. Comparisons
of other outcomes were based on proportional hazards models for the
cause-speciﬁc hazard [22] (chronic GVHD, relapse, and NRM) and Cox pro-
portional hazards models (OS). The proportional hazards assumption was
checked by examination of Schoenfeld residuals and Grambsch and Ther-
neau’s lack-of-ﬁt test [23]. All tests were 2 sided and P values .05 were
considered as indicating signiﬁcant association. Analyses were performed
using the R statistical software version 2.15.2 [24,25]. The joint modeling
was performed using the JM package [19].
RESULTS
General Outcomes and Infectious Complications
Main patient, disease, and transplantation characteristics
are summarized in Table 1. Thirty-six patients underwent
transplantation fromaMMUDand 30 fromUCB. Patientswho
underwent transplantation from UCB were signiﬁcantly
younger, had different GVHD prophylaxis and, as expected,
had different cytomegalovirus (CMV) serology proﬁles, as all
UCB units were CMV-seronegative. Median follow-up from
transplantationwas 51months (range, 4 to 76): 52 forMMUDand 50 for UCB patients. No relapse or death were observed
beyond 48 months. Detailed estimates of outcomes are given
for each group in Table 2. None of the main outcomes, ie,
chronic GVHD, relapse rates, NRM, and OS, signiﬁcantly
differed after 3 months between patient groups.
We then studied infection rates after MMUD or UCB
transplantation. Although not signiﬁcantly different between
Table 2
Cumulative Incidence of Outcomes and Overall Survival after 3 Months ac-
cording to Donor Group
Outcome mmUD UCB P Value
No. patients 36 30
Chronic GVHD
Cumulative incidence at 4 years 71% (52-84) 62% (41-77) .64
Relapse
Cumulative incidence at 4 years 20% (9-36) 24% (10-41) .66
Nonrelapse mortality
Cumulative incidence at 4 years 30% (15-46) 30% (15-47) .78
Overall survival
Cumulative incidence at 4 years 60% (45-80) 62% (47-83) .96
Data are estimates and 95% conﬁdence intervals.
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lasting immune defect after these transplantations from
alternative donors, as the 18-month cumulative incidences of
infectious-related death were 8% and 3%, and of infections
were 72% and 57% after MMUD and UCB transplantation,
respectively. Cumulative incidences of infections are shown
in Figure 1. Table 3 summarizes the cumulative incidences of
infectious complications and Table 4 provides details on
microbiological species and sites of infection. Overall, 25
and 17 patients developed 66 and 60 infections between
3 and 18 months after MMUD and UCB transplantation,Figure 1. Cumulative incidence of infections beyond 3 months according to donor
bacterial infections (B), viral infections (C), and fungal infections (D).respectively. Rates of infection per 12 patient-month were
roughly 2 overall (1 for bacterial, .9 for viral, and .3 for fungal
infections) (Table 3). Thirty-three and 28 bacterial infections
were recorded for MMUD and UCB groups, respectively;
pneumonias were the most frequent infections, documented
bacteriologically in 60%. Bacterial species ﬁt with what could
be expected during this period of time after transplantation
(see Table 4 for details). Twenty-six and 21 viral infections
were recorded between 3 and 18 months after MMUD and
UCB HSCT, respectively, with late CMV reactivation being the
most frequent. Seven and 9 fungal infections were recorded
for MMUD and UCB groups, respectively; pulmonary asper-
gillosis being the most frequent.
Immune Reconstitution
Data on main circulating cell phenotypes were available
for 75%, 82%, and 57% versus 93%, 80%, and 76% of the
disease-free survivors at 3, 6, and 12 months after MMUD
versus UCB HSCT, respectively (Figure 2). When assessed
globally, patients who underwent HSCT from alternative
donor (MMUD or UCB) had early NK cells and CD8þ T cells
reconstitution but prolonged, profound, CD4þ T cells deﬁ-
ciency. In fact, the median of absolute CD4þ T cells count did
not reach .5  109/L by 1 year after transplantation in both
MMUD and UCB cohorts. Compared with MMUD recipients,
UCB recipients demonstrated higher absolute numbers of NKgroup, MMUD (black line) versus UCB (grey line); infections of any type (A),
Table 3
Cumulative Incidence and Rates of Infection after 3 Months according to
Donor Group
Outcome MMUD UCB P Value
No. patients 36 30
All infections
Cumulative incidence at
18 months
72% (54-84) 57% (37-73) .34*
Rate per 12 patient-month 2.2 (1.7-2.8) 2.3 (1.8-3.0) .84y
Bacterial infections
Cumulative incidence at
18 months
47% (30-63) 40% (22-57) .55*
Rate per 12 patient-month 1.0 (.7-1.5) 1.0 (.6-1.4) .70y
Viral infections
Cumulative incidence at
18 months
47% (30-63) 40% (22-57) .58*
Rate per 12 patient-month .9 (.7-1.3) .9 (.6-1.4) .55y
Fungal infections
Cumulative incidence at
18 months
20% (9-34) 20% (8-36) .94*
Rate per 12 patient-month .2 (.1-.5) .4 (.2-.7) .42y
Life-threatening infections
Cumulative incidence at
18 months
6% (1-17) 3% (0-15) .66*
Rate per 12 patient-month .1 (.0-.3) 0 (0-.3) .73y
Infection-related mortality
Cumulative incidence at
18 months
8% (2-20) 3% (<1-15) .38z
Data are estimates and 95% conﬁdence intervals.
* Overall tests are Gray’s tests.
y Score tests in Prentice-Williams-Peterson.
z Cause-speciﬁc proportional hazards models.
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plantation, as well as a trend of higher B cell counts at 6
months (Figure 2). To the contrary, lower counts of total T
cells and CD8þ T cells up to 1 year after transplantation and a
trend of lower CD4þ T cell counts at 3 and 6 months were
observed in UCB recipients as compared with MMUD re-
cipients. When analyzed in detail looking for the proportions
of memory and naïve subsets among CD4þ and CD8þ T cells
and among B cells, the differences between the 2 cohorts
were minimal and only applied to the 3-month time point
(Figure 3). Most B cells were of naïve phenotype from 3
months to 1 year after transplantation. There was no differ-
ence for absolute circulating Treg afterMMUD and UCBHSCT.Impact of Immune Reconstitution on Infection Risk
First, we assessed the impact of early (baseline and 3
months) clinical factors and early (3 months) immunological
factors on risks for late infections (overall, bacterial, and
viral). On univariate analysis, donor source (UCB versus
MMUD) was not associated with infections. Variables asso-
ciated with risks of infection on univariate analysis were the
3-month cumulative corticosteroid dose and circulating
immune cells counts at 3 months (see Supplementary
Table 2). Results of the multivariate analysis are shown in
Table 5. On multivariate analysis, the 3-month cumulative
corticosteroid dose did not retain signiﬁcance. A high CD4þ T
cell count at 3 months was linked with decreased risks of
overall and viral (but not bacterial) infections. Among the
CD4þ T cell subset at 3 months, an increased percentage of
late effector memory cells was associated with decreased
risks of overall, viral, and bacterial infections, and a higher
percentage of central memory cells was associated with
decreased risks of overall and bacterial infections. To the
contrary, high CD8þ T cells count at 3 months was linked
with increased risks of overall and viral (but not bacterial)infections. A higher proportion of effector memory cells
among the CD8þ T cell compartment at 3 months was
associated with a reduced risk of bacterial infections but
predicted higher risk of viral infections, as did a higher per-
centage of late effector memory CD8þ T cells.
Finally, we assessed the association between immune cell
counts at any time from 3 to 12 months after alternative
transplantation and hazard of ﬁrst infection of any type,
based on a joint model for the evolution of cell sub-
populations after 3 months and the hazard of infection
(Table 6). The same immune cell populations were found to
be associatedwith risks of infections as those observed at the
speciﬁc 3-month time point, with the addition of NK cells, B
cells, and effector memory CD4þ T cells. High counts of CD4þ
T cells (total and all memory subtypes) and also of NK cells
and B cells were protective against late infections, whereas
increased numbers of total CD8þ T cells and effector memory
CD8þ T cells were associated with higher risks of infections.
The total count of late effector memory CD8þ T cells was not
relevant using this joint model.
DISCUSSION
When there is a lack of a sibling or suitable MUD, alter-
native donors such as MMUD or UCB are often used for
allogeneic HSCT. However, these types of transplantation,
especially UCB, have been linked to high infection risk
(reviewed by Ballen et al. [1]), but detailed analyses
comparing infection and immune recovery in these patients
subset are scarce. Indeed, the 18-month cumulative in-
cidences of infection-related death rates were in the 5%
range, and that of infections was nearly 60% overall in our
study. Rates of infection per 12 patient-month were roughly
2 overall. Memory, naïve CD4þ and CD8þ T cells, naïve B cells,
and Treg reconstitution between the 2 sources were roughly
similar between the 2 transplantation. Absolute CD4þ T cells
hardly reached 500/mL by 1 year after transplantation and
most B cells were of naïve phenotype. Finally, this study
provides a detailed analysis on correlations between im-
mune reconstitution and infection. Low CD4þ and high CD8þ
T cells absolute counts were linked to increased infection
risk. When analyzed separately, the absolute counts of both
CD4þ and CD8þ T cells at 3 months affected risks for viral but
not for bacterial infections. The proportions of naïve and
memory subsets among the T cell compartments at 3 months
also predicted infections after alternative transplantation;
low percentage of central memory CD4þT cells was associ-
ated with higher risks of infections (overall and bacterial), as
were low percentage of late effector memory CD4þT cells
(overall, bacterial, and viral infections) and high percentage
of effector and late effector memory CD8þT cells (viral
infections).
Previous studies have already reported infection risk
either overall or of speciﬁc types, especially after UCB
transplantation [5,9,26-38] but few aimed to compare this
risk with transplantation from other alternative sources.
Parody et al. [28] reported a higher incidence of bacterial
infections before day 100 after UCB transplantation, but at 3
years the risks of these and other infections were similar
after transplantation from either UCB or unrelated donors.
Mikulska et al. focused their analysis on CMV infection and
reported a higher incidence of late CMV infection and a
longer duration of CMV infection after transplantation from
UCB as compared with unrelated donor or mismatched
related donor [27]. These results on CMV infection were not
conﬁrmed by Walker et al. [31]. Finally, Hamsa et al. [32]
Table 4
Detailed Infections Observed between 3 and 18 Months after Transplantation; Location and Microbial Species
Infection MMUD UCB
No. of infected patients 25 17
No. of infectious events 66 60
Bacterial infections 33 28
Bacteremia 6 3
Gram-positive
Enterococcus spp. 2 0
Gram-negative
Escherichia coli 2 1
Pseudomonas aeruginosa 0 1
Other 2 (1 Klebsiella pneumoniae,
1 Enterobacter cloacae)
1 (1 Bacteroides fragilis)
Pneumonia 22 17
Gram-positive
Streptococcus pneumoniae 4 1
Viridans group streptococci 1 0
Gram-negative
Escherichia coli 2 2
Pseudomonas aeruginosa 1 6
Other 5 (3 Haemophilus parainﬂuenzae,
1 Haemophilus inﬂuenzae,
1 Capnocytophaga)
1 (1 Klebsiella pneumoniae)
Not identiﬁed 9 7
Urinary tract infections 2 3
Gram-negative
Escherichia coli 0 2
Other 0 1 (1 Proteus Mirabilis)
Not identiﬁed 2 0
Other sites 3 5
Ileo-colitis 1 (1 Campylobacter) 1 (not identiﬁed)
Acute cholecystitis 2 (1 not identiﬁed) 0
Cutaneous infections (cellulitis, cutaneous abscesses) 0 2 (1 Enterobacter cloacae,
1 Staphylococcus aureus)
Upper respiratory tract infections 0 1 (1 Pseudomonas aeruginosa)
Septical shock of unknown origin 0 1
Viral infections 26 21
CMV 15 8
CMV infection 14 7
CMV disease 1 (1 hepatitis) 1 (1 retinitis)
EBV 3 1
EBV reactivation 2 1
EBV lymphoproliferative disease 1 0
Adenovirus 1 5
Reactivation 0 3
Disease 1 (1 colitis) 2 (1 colitis, 1 disseminated form
with colitis, cystitis and pneumonitis)
Other Herpes viruses 3 2
HSV 1-2 (severe form) 3 (2 viremia with extensive stomatitis,
1 extensive genital herpes)
1 (1 viremia with extensive stomatitis)
HHV-6 0 1
Respiratory virus 4 5
Parainﬂuenza 0 1
Inﬂuenza 0 2
RSV 3 1
Others 1 (1 BK JC-associated progressive
multifocal leukoencephalopathy)
1 (1 Metapneumovirus)
Invasive fungal infections 7 9
Candidemia 0 2 (2 Candida glabrata)
Invasive pulmonary aspergillosis 6 (2 proven, 3 possible, 1 probable) 6 (1 proven, 3 possible, 2 probable,)
Mucor mycosis 0 1
Other 1 (1 Pneumocystosis) 0
Toxoplasmosis 0 2
CMV indicates cytomegalovirus; EBV, Epstein-Barr virus; HSV, herpes simplex virus; HHV, human herpes virus; RSV, respiratory syncytial virus.
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at the early time points (before day þ50) after trans-
plantation, after UCB compared with MUD allogeneic trans-
plantation, in adults. Altogether, these studies, although
conﬁrming the high infection rates early after UCB trans-
plantation, cannot really be compared with our analysis that
mainly aimed to study the long-term infection types andrates after 3 months and to compare this with immune
reconstitution parameters.
Few studies aimed to compare the immune reconstitution
between UCB transplantation in adult with that after trans-
plantation from other sources. Kanda et al. [39] studied the
immunologic reconstitution after allogeneic HSCT from UCB
in adult recipients and characterized the kinetics and extent
Figure 2. Distribution of sequential cellular subsets by absolute numbers after transplantation. Box and whisker plots display the median, 25th, and 75th percentile
of the distribution (box), and whiskers extend to the most extreme data points. P values are corrected for testing at repeated time points within each subpopulation.
White boxes refer to MMUD and grey boxes to UCB transplantation. The number of available data at each time point for each cohort is also displayed. Circulating
immune cells phenotypes were assessable for 27 of 36, 28 of 34, and 15 of 26 of the disease-free survivors at 3, 6, and 12 months after MMUD HSCT, respectively; and
for 28 of 30, 20 of 25, and 16 of 21 of the disease-free survivors at 3, 6, and 12 months after UCB HSCT, respectively.
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(n ¼ 29), matched sibling donor (n ¼ 33), or MUD (n ¼ 33)
transplantation. There were no differences in the immune
recovery proﬁle of matched sibling donor and MUD re-
cipients, but signiﬁcantly lower levels of CD3þ, CD4þ, and
CD8þ T cells were observed in UCB recipients until 6 months
after transplantation. Lower levels of Treg persisted until 1
year after transplantation. They concluded that compared
with HLA-identical matched sibling donor and MUD adult
HSCT recipients, UCB transplantation recipients experienced
a slower quantitative lymphoid recovery in the ﬁrst 3
months, but these differences disappeared by 6 to 12 months
after transplantation. Although large and providing useful
estimates, this study cannot be compared with ours, whichaims to compare UCB and MMUD transplantation recipients.
Jacobson et al. [7] aimed to deﬁne the differences in immune
reconstitution between UCB and MUD transplantation. They
performed a detailed prospective analysis of immune
reconstitution in 42 double UCB recipients and 102 MUD
peripheral blood stem cell recipients. Reconstitution of CD3þ
T cells was signiﬁcantly delayed in the UCB cohort compared
with the MUD cohort for 1 to 6 months after transplantation,
including naive and memory CD4þ T cells, Treg, and
CD8þ T cells. In contrast, they found that CD19þ B cells
recovered more rapidly in the UCB cohort and numbers re-
mained signiﬁcantly greater than in MUD patients from 3 to
24 months after transplantation. However, CD19þ B cells
subsets were not studied and this difference might be due to
Figure 3. Distribution of sequential relative cellular T and B subsets after transplantation. Box and whisker plots display the median, 25th, and 75th percentile of the
distribution (box), and whiskers extend to the most extreme data points. P values are corrected for testing at repeated time points within each subpopulation. White
boxes refer to MMUD and grey boxes to UCB transplantation. The number of available data at each time point for each cohort is also displayed. T cell subsets were
assessable for 21 of 36, 25 of 34, and 14 of 26 of the disease-free survivors at 3, 6, and 12 months after MMUD HSCT, respectively; and for 15 of 30, 12 of 25, and 16 of
21 of the disease-free survivors at 3, 6, and 12 months after UCB HSCT, respectively.
S. Servais et al. / Biol Blood Marrow Transplant 20 (2014) 507e517514an increased number of B1-like B cells. NK cells in their
cohort, as in ours, recovered more rapidly in UCB recipients.
As in our own study, these results suggest that increased risk
of infections is speciﬁcally associated with delayed recon-
stitution of all major T cell subsets. Other studies (including
some of our group) speciﬁcally looked for immune recon-
stitution after UCB transplantation but did not aim to
compare results with other sources (MUD or MMUD)
[5,7,27,34,39-43] and are, thus, hardly comparable to the
results we present herein.
Finally, even fewer studies aimed to correlate infection
risk to immune reconstitution in the setting of trans-
plantation from alternative donors. Indeed, to the best of ourknowledge, only the study by Bartelink et al. [44] can be
compared with ours. In their study, the authors investigated
differences in immune reconstitution with different cell
sources and the association between the kinetics of immune
reconstitution and mortality. Immunophenotyping was per-
formed in children who had undergone HSCT between 2004
and 2008. Lymphocyte reconstitution in theﬁrst 90 days after
HSCT was studied in relation to mortality in 3 HSCT groups:
matched sibling bone marrow recipients (35 patients), un-
related donor recipients (32 patients), and UCB recipients (36
patients). The median age of recipients was 5.9 years. They
reported that in the ﬁrst 90 days after HSCT, faster B cell and
NKcell reconstitution anddelayed Tcell reconstitution inUCB
Table 5
Multivariable Analysis of Association of Patient Characteristics (at Baseline and at 3 Months) and Immune Recovery (at 3 Months) with Infections
Variable Overall Infections Bacterial Infections Viral Infections
All Patients Subset with CD45RA/CCR7
Markers
All Patients Subset with CD45RA/
CCR7 Markers
All Patients Subset with CD45RA/
CCR7 Markers
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Steroid 3-mo. AUC (per 10 mg/kg) 1.02 (.99-1.05) .25 1.16 (1.06-1.28) .002 1.02 (.98-1.07) .27 1.10 (.99-1.23) .080 1.00 (.96-1.05) .86 1.18 (.97-1.44) .10
Immune cells at 3 months
CD4 þ T cells/mm3, as log .45 (.30-.68) .0001 .37 (.13-1.00) .049 .56 (.30-1.04) .068 .37 (.11-1.29) .12 .20 (.09-.47) .0002 .20 (.014-2.84) .23
CD8 þ T cells/mm3, as log 1.59 (1.10-2.31) .014 3.12 (1.50-6.49) .002 1.30 (.71-2.41) .40 2.83 (.87-9.26) .084 2.54 (1.36-4.75) .003 7.67 (1.57-37.4) .012
NK cells/mm3, as log .54 (.28-1.02) .058 1.82 (.46-7.13) .39 .40 (.15-1.06) .066 4.09 (.55-3.3) .17 .66 (.25-1.70) .39 .19 (.005-7.19) .37
B cells/mm3, as log [xþ1] .87 (.63-1.20) .40 .87 (.45-1.67) .68 .73 (.44-1.20) .22 .57 (.21-1.52) .26 1.03 (.62-1.70) .91 1.59 (.22-11.7) .65
Percent of naive CD4 T cells, per 10% - - .95 (.76-1.17) .62 - - .74 (.53-1.03) .073 - - 1.78 (1.01-3.14) .048
Percent of central memory CD4 T cells, per 10% - - .73 (.60-.88) .001 - - .70 (.57-.86) .0009 - - .62 (.38-1.01) .056
Percent of late effector memory CD4 T cells, per 10% - - .37 (.23-.59) <.0001 - - .32 (.18-.55) <.0001 - - .25 (.07-.95) .042
Percent of effector memory CD8 T cells, per 10% - - .99 (.78-1.26) .94 - - .72 (.53-.98) .040 - - 2.53 (1.18-5.42) .017
Percent of central memory CD8 T cells, per 10% - - .93 (.44-1.97) .86 - - 1.23 (.33-4.62) .76 - - 3.22 (.85-12.2) .086
Percent of late effector memory CD8 T cells, per 10% - - .98 (.79-1.22) .86 - - .87 (.68-1.13) .30 - - 2.51 (1.23-5.15) .012
HR indicates adjusted hazard ratio; CI, conﬁdence interval.
Logarithms are decimal logarithms. The log (x þ 1) transform was used for subpopulations with zero counts.
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Table 6
Joint Modeling of Evolution of Immune Cell Populations and Hazard of First Infection of Any Type
Subpopulation Linear Trend Over Follow-up Association of Subpopulation
with Infection
Slope/mo. (95% CI) P HR (95% CI) P
CD4 þ T cells/mm3, as log .05 (.03-.07) < .0001 .41 (.35-.49) < .0001
CD8 þ T cells/mm3, as log .06 (.04-.08) < .0001 1.18 (1.02-1.37) .028
NK cells (CD3-CD56þ) mm3, as log .01 (-.01-.02) .36 .22 (.19-.25) <.0001
B cells (CD19þ)/mm3, as log (xþ1) .14 (.09-.18) < .0001 .46 (.35-.61) < .0001
Naive CD4 T cells (CD4þCD45RAþCCR7þ)/mm3, as log (xþ1) .03 (-.01-.07) .18 .84 (.64-1.11) .21
Central memory CD4 T cells (CD4þCD45RA-CCR7þ)/mm3, as log .05 (.02-.08) .0002 .50 (.39-.64) < .0001
Effector memory CD4 T cells (CD4þCD45RA-CCR7-)/mm3, as log .04 (.01-.07) .004 .50 (.39-.64) < .0001
Late effector memory CD4 T cells (CD4þCD45RAþCCR7-)/mm3, as log (xþ1) .04 (.01-.07) .005 .52 (.32-.84) .008
Ratio CD4þCCR7þ/CD4þCCR7- T cells, as log .00 (-.02-.03) .74 .85 (.33-2.17) .74
Naive CD8 T cells (CD8þCD45RAþCCR7þ)/mm3, as log .04 (0-.08) .045 .89 (.66-1.21) .47
Central memory CD8 T cells (CD8þCD45RA-CCR7þ)/mm3, as log .03 (0-.06) .065 1.37 (.82-2.28) .23
Effector memory CD8 T cells (CD8þCD45RA-CCR7-)/mm3, as log .05 (.02-.07) .0004 2.48 (2.01-3.06) < .0001
Late effector memory CD8 T cells (CD8þCD45RAþCCR7-)/mm3, as log .07 (.04-.10) < .0001 1.17 (.95-1.45) .15
Ratio CD8þCCR7þ/CD8þCCR7- T cells, as log .02 (.06-.01) .22 .68 (.47-1.00) .051
HR indicates adjusted hazard ratio; CI, conﬁdence interval.
Logarithms are decimal logarithms. The log (x þ 1) transform was used for subpopulations with zero counts.
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donor recipients. Of the lymphocyte subsets they investi-
gated, a large number of NK cells and amore rapid CD4þ Tcell
immune reconstitution were the only predictors of lower
mortality risk in all cell source groups. This study clearly
differed from ours in several ways, including patients’ age,
study time point (ﬁrst 3 months after transplantation), and a
far less detailed study on infection risk.
Our study has inherent limits of retrospective analyses;
however, we paid much attention to retrieve extensive data
on infection beyond 3 months. Patients are followed in our
outpatient clinic or in consultation, and they are either from
the Paris area or not redirected to their primary hospital
before 2 years after transplantation (and even in this case,
they are followed annually at the hospital Saint Louis).
Furthermore, even if patient numbers seem low at a ﬁrst
glance, the number of patients who underwent trans-
plantation from alternative donors (MMUD or UCB) remains
relatively few, as compared with those who underwent
transplantation from sibling donors or from MUD.
In conclusion, patients who underwent transplantation
from alternative donors represent a population with very
high risk of infection. Detailed phenotypic analysis of im-
mune reconstitution may help to evaluate infection risk and
to adjust infection prophylaxes. Physicians not directly
involved in the daily care of these patients should be aware of
this situation, given the growing numbers of patients who
underwent transplantation with alternative donors who
survive long term.ACKNOWLEDGMENTS
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